OCULOGICA

OCULOGICA

The EyeBOX takes the guesswork out of concussion assessment for more precise diagnosis and treatment.

Founded 2013

New York, United States 15 employees Venture round Total: $25.31M Health Care

OCULOGICA offers a revolutionary innovation in the healthcare industry with its EyeBOX technology, aiming to provide more accurate and objective concussion assessments. Founded in 2013 and headquartered in the United States, the company has gained recognition for its groundbreaking approach, as evidenced by its inclusion in the 2020 Fast Company Most Creative Companies list. The EyeBOX sets itself apart with its ability to collect and analyze over 100,000 data points across 67 domains of eye movement within under 4 minutes. This comprehensive analysis enables the generation of unique, objective assessments for each patient, without requiring baseline data or individual calibration, thereby mitigating the potential influence of patient will on the results. One of the key strengths of the EyeBOX lies in its baseline-free nature, which eliminates the need for pre-incident patient data. Moreover, its 67-point analysis provides a level of diagnostic precision that surpasses current standards of care, offering a more comprehensive assessment of brain function beyond just symptoms. The technology's simplicity and calibration-free testing make it accessible across various patient demographics, including pre-verbal and verbally impaired individuals. The company recently secured a significant $7.57M Venture Round investment on 13 May 2024, signifying the confidence of investors in OCULOGICA's innovative approach to concussion assessment. With its pioneering technology and strong financial backing, OCULOGICA is poised to make a significant impact in the healthcare industry by improving patient outcomes and setting new standards for concussion diagnosis and treatment.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	$7.57M	-		13 May 2024
Venture Round	$4.05M	-		23 Jun 2022
Debt Financing	Undisclosed	-		23 Jun 2022
Grant	$2.00M	1	U.S. Army Medical Research & Development Command	18 May 2021
Series A	$8.18M	4	Colle Capital, Golden Seeds +2	17 Jul 2019
Angel Round	Undisclosed	1	Nebraska Angels	01 Jan 2017
Seed Round	$1.22M	2	Golden Seeds, Southeast Minnesota Capital Fund	01 May 2016
Seed Round	$1.69M	3	Golden Seeds, Sofia Fund +1	17 Mar 2016
Seed Round	$599.97K	-		20 May 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

$7.57M

13 May 2024

Venture Round

$4.05M

23 Jun 2022

Debt Financing

Undisclosed

23 Jun 2022

Grant

$2.00M

U.S. Army Medical Research & Development Command

18 May 2021

Series A

$8.18M

Colle Capital, Golden Seeds +2

17 Jul 2019

Angel Round

Undisclosed

Nebraska Angels

01 Jan 2017

Seed Round

$1.22M

Golden Seeds, Southeast Minnesota Capital Fund

01 May 2016

Seed Round

$1.69M

Golden Seeds, Sofia Fund +1

17 Mar 2016

Seed Round

$599.97K

20 May 2014

FAQ About OCULOGICA

The EyeBOX takes the guesswork out of concussion assessment for more precise diagnosis and treatment.

OCULOGICA was founded in 2013.

OCULOGICA is headquartered in New York, United States.

OCULOGICA operates in Health Care. Its work centres on Neuro-diagnostics, Brain Injury, TBI and Concussion.

OCULOGICA has approximately 15 employees.

OCULOGICA has completed 9 funding rounds, raising a total of $25.31M. The latest funding stage is Venture round.

Top alternatives and competitors to OCULOGICA include SyncThink, Cerora, Inc., Cognision, Astek Diagnostics, KISSH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

OCULOGICA and SyncThink are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About OCULOGICA

Funding Rounds & Investors (9)

OCULOGICA Alternatives & Competitors

FAQ About OCULOGICA